請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44559完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Meng-Chin Jan | en |
| dc.contributor.author | 冉孟芹 | zh_TW |
| dc.date.accessioned | 2021-06-15T03:51:07Z | - |
| dc.date.available | 2015-09-09 | |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-07-14 | |
| dc.identifier.citation | 1. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92(14):1159-64.
2. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292(15):771-4. 3. Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002;31(5):1008-15. 4. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12(9-10):S294-308. 5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-38. 6. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119(8):1946-52. 7. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene;29(16):2309-24. 8. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000;156(4):1117-32. 9. Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248(4953):361-4. 10. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188(2):341-50. 11. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17(2):71-91. 12. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72. 13. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49(5 Suppl):S72-84. 14. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73. 15. Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 16. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74. 17. You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med 2004;36(3):215-24. 18. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194(5):594-9. 19. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57(1):91-7. 20. Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137(5):1687-97. 21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521-31. 22. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373(9663):582-92. 23. 黃宣豪. Interferon gamma訊號路徑上之基因變異與B型肝炎病毒複製活性關係: 臺灣大學. 24. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55. 25. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77(1):68-76. 26. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97(7):1655-65. 27. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369(6475):31-7. 28. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997;159(11):5197-200. 29. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A;107(2):798-802. 30. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003;23(1):21-38. 31. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75(2):163-89. 32. Kuwahara Y, Kusugami K, Morise K, Shimokata K. Effect of recombinant gamma interferon on natural killer cell activity in patients with gastric cancer. Gastroenterol Jpn 1987;22(4):428-34. 33. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001;31(11):3138-46. 34. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68(12):8056-63. 35. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188(12):2199-204. 36. Whitmire JK, Benning N, Whitton JL. Cutting edge: early IFN-gamma signaling directly enhances primary antiviral CD4+ T cell responses. J Immunol 2005;175(9):5624-8. 37. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993;259(5102):1739-42. 38. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84(3):443-50. 39. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101(17):6669-74. 40. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994;91(9):3764-8. 41. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91. 42. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4(1):25-36. 43. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A 1995;92(26):12398-402. 44. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A 2004;101(6):1743-7. 45. Kirschberg O, Schuttler C, Repp R, Schaefer S. A multiplex-PCR to identify hepatitis B virus--enotypes A-F. J Clin Virol 2004;29(1):39-43. 46. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62(5):1198-211. 47. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101(19):1348-55. 48. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27(4):670-84. 49. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81(8):4215-25. 50. Hohler T, Reuss E, Adams P, Bartsch B, Weigmann B, Worns M, et al. A genetic basis for IFN-gamma production and T-bet expression in humans. J Immunol 2005;175(8):5457-62. 51. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008;17(12):3450-6. 52. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178(5):1541-54. 53. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76(21):10702-7. 54. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74(9):4165-73. 55. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007;81(14):7351-62. 56. Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ, et al. Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci;55(4):1113-9. 57. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003;12(19):2541-6. 58. Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis 1993;16(5):709-13. 59. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006;55(8):1183-7. 60. London WT, Drew JS. Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment. Proc Natl Acad Sci U S A 1977;74(6):2561-3. 61. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122(7):1756-62. 62. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005;12(5):456-64. 63. Le Gall S, Stamegna P, Walker BD. Portable flanking sequences modulate CTL epitope processing. J Clin Invest 2007;117(11):3563-75. 64. Moszczynski P, Zabinski Z, Moszczynski P, Jr., Rutowski J, Slowinski S, Tabarowski Z. Immunological findings in cigarette smokers. Toxicol Lett 2001;118(3):121-7. 65. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999;192(1):48-53. 66. Geissler M, Gesien A, Wands JR. Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics. Hepatology 1997;26(3):764-70. 67. Larkin J, Clayton MM, Liu J, Feitelson MA. Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice. Hepatology 2001;34(4 Pt 1):792-7. 68. Tanaka S, Isoda F, Yamakawa T, Ishihara M, Sekihara H. T lymphopenia in genetically obese rats. Clin Immunol Immunopathol 1998;86(2):219-25. 69. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 2001;54(3):347-54. 70. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77(8):4911-27. 71. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188(12):2205-13. 72. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008;45(4):963-70. 73. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology;138(2):682-93, 693 e1-4. 74. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682-7. 75. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008;118(5):1835-45. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44559 | - |
| dc.description.abstract | 背景: 個體間HBV病毒量具有寬廣的變異。根據先前的動物實驗，IFN-γ對HBV清除扮演著重要的角色。本研究首先利用家族樣本與一群個體互相獨立之樣本，探討IFN-γ表現與單時點與長期病毒量測量值之間的關係；其次，調查影響HBV帶原者IFN-γ表現之決定因子。
材料/方法:透過肝細胞癌指標個案，我們收集其親屬總計309家共849位HBV帶原者(477位男性和372位女性)納入研究分析。個體互相獨立之樣本來自一個包含1143名男性HBV帶原者的病例世代樣本，其源自於追蹤長達17年之一個前瞻性世代。 結果: 我們發現IFN-γ表現與病毒量間有負相關存在，特別是在女性 (p=0.0168)和HBV基因型C感染者 (p=0.0285)身上。家族和個體互相獨立之樣本皆發現抽菸及喝酒與降低的IFN-γ表現有關。 結論:本研究顯現，IFN-γ表現在HBV帶原者體內具有控制病毒量之作用，已知的肝細胞癌危險因子，包括抽菸、喝酒，皆和IFN-γ表現呈現負相關。 | zh_TW |
| dc.description.abstract | Background & Aims
There is remarkable variation in the degree of viremia among hepatitis B virus (HBV) carriers. In experimental studies, IFN-γ is critical for HBV clearance. The purpose of this study is two-fold: first, to assess the association of IFN-γ expression with cross-sectional and longitudinal measures of HBV viral load in both a family sample and a sample of unrelated individuals; second, to investigate factors that might determine IFN-γ expression among chronic HBV carriers. Materials and Methods Family-based study consisted of 849 consecutive HBV carriers (477 men and 372 women) from 309 different families each ascertained via a single proband patient with hepatocellular carcinoma (HCC). Unrelated subjects included 1143 male HBV carriers enrolled from an existing case-cohort study nested within a prospective cohort of 2903 HBV carriers followed for up to 17 years. Results We found an inverse association between IFN-γ expression and the degree of viremia, particularly for women (p=0.0168) and those infected with genotype C HBV (p=0.0285). Tobacco and alcohol use were associated with reduced IFN-γ expression in both family sample and unrelated subjects. Conclusions Our results suggest that IFN-γ expression is involved in the control of HBV viremia among chronic HBV carriers. IFN-γ expression is influenced by putative HCC risk factors, such as cigarette smoking and alcohol consumption. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T03:51:07Z (GMT). No. of bitstreams: 1 ntu-99-R97842009-1.pdf: 380405 bytes, checksum: 315640b8dae86ab73ecfeb384f5023f3 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 目錄
致謝 ii 中文摘要 iii Abstract iv 目錄 vi 圖表目錄 vii 前言 1 材料與方法 6 結果 9 討論 13 參考文獻 18 附錄一 33 | |
| dc.language.iso | zh-TW | |
| dc.subject | 慢性B型肝炎 | zh_TW |
| dc.subject | 病毒量 | zh_TW |
| dc.subject | 干擾素-gamma | zh_TW |
| dc.subject | viremia | en |
| dc.subject | interferon-gamma | en |
| dc.subject | chronic hepatitis B | en |
| dc.title | 干擾素-gamma的表現在慢性B 型肝炎病毒量控制所扮演的角色 | zh_TW |
| dc.title | Control of Viremia in Chronic Hepatitis B: Emphasis on the Role of Interferon-gamma Expression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 莊雅惠(Ya-Hui Chuang) | |
| dc.contributor.oralexamcommittee | 吳肇卿(Jaw-Ching Wu),熊昭(Chao A. Hsiung),蔡孟勳(Mong-Hsun Tsai) | |
| dc.subject.keyword | 慢性B型肝炎,干擾素-gamma,病毒量, | zh_TW |
| dc.subject.keyword | chronic hepatitis B,interferon-gamma,viremia, | en |
| dc.relation.page | 33 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-07-14 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 未授權公開取用 | 371.49 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。